"Designing Growth Strategies is in our DNA"

Cutaneous B-cell Lymphoma Treatment Market Size, Share & Industry Analysis, By Type (Radiation Therapy, Chemotherapy, Monoclonal Antibodies, Others (Corticosteroids, Interferons, etc.)), By End-user (Hospitals, Speciality Clinics, Others) and Regional Forecast, 2021-2028

Region : Global | Report ID: FBI101515 | Status : Ongoing

 

KEY MARKET INSIGHTS

Cutaneous B-cell lymphoma is a rare form of cancer that ocurs in the white blood cells and attacks the skin. The cutaneous B-cell lymphoma is classified into primary cutaneous follicle center lymphoma, primary cutaneous marginal zone B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma, and intravascular diffuse large B-cell lymphoma.


B-cell lymphomas account for 85 percent of all non-Hodgkin lymphoma (NHL) cases in the United States. The disease affects men and women equally, and any age group can be affected. Diagnosis of cutaneous b-cell lymphoma includes various tests including imaging tests, bone-marrow biopsies, blood test, and skin biopsy test, among others.


Increasing prevalence of the non-Hodgkin lymphoma (NHL) cases is one of the major factors propelling the cutaneous B-cell lymphoma treatment market growth. According to the an article published by NCBI in 2015, primary cutaneous lymphomas (PCL) are the most recurrent extra-nodal lymphomas, with incidence of approximately 10 cases per million population per year, out of which 20-30% are primary cutaneous B-cell lymphomas (PCBCL).


To gain extensive insights into the market, Request for Customization


The increasing prevalence of primary cutaneous B-cell lymphomas is one of the major factor presenting a large patient pool requiring treatment, subsequently driving the growth of the global market. Increasing investment in research and development for the development of the novel products in order to cure cutaneous B-cell lymphoma is one of the major factor anticipated to propel the cutaneous B-cell lymphoma treatment market growth during the forecast period of 2019-2026.


In October 2017, U.S. Food and Drug Administration approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. The new product approvals for the treatment of B-cell lymphoma in developed and developing countries is one of the major factor likely to drive the growth of the global cutaneous B-cell lymphoma market during forecast period.


On the flip side, the lack of approved drugs for the treatment of cutaneous b-cell lymphoma, and high cost of the treatment are some of the factors restraining the growth of the global cutaneous B-cell lymphoma market.


Key Players Covered


The major companies covered in the global cutaneous B-cell lymphoma treatment market report include Kite Pharma, Genentech, Inc., Novartis AG, Epizyme, Inc., NanoString Technologies, Inc., Amgen Inc., Johnson & Johnson Services, Inc. and other players.


Segmentation






















 ATTRIBUTE


 DETAILS

By Type




  • Radiation Therapy

  • Chemotherapy

  • Monoclonal Antibodies

  • Others (Corticosteroids, Interferons, etc.)



By End-user




  • Hospitals

  • Speciality Clinics

  • Others



By Geography




  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



As per the current cutaneous B-cell lymphoma treatment market trends, chemotherapy among the type accounted for the largest market share in the global cutaneous B-cell lymphoma treatment market in 2018.


Key Insights



  • Prevalence of Lymphoma, Key Countries/ Regions, 2018

  • New Product Launches, by Key Market Players

  • Pipeline Analysis

  • Key mergers and acquisitions


Regional Analysis


The global cutaneous B-cell lymphoma treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global cutaneous B-cell lymphoma treatment market in 2018 followed by Europe. Asia Pacific is anticipated to grow at significant CAGR during the forecast period due increased investment by key market players in the research and development of the treatment for the cutaneous B-cell lymphoma. Latin America and Middle East and Africa account for relatively lower share and are projected to grow at a comparatively lower CAGR during the forecast period.


Cutaneous B-cell Lymphoma Treatment Industry Developments



  • In June 2019, Kite Pharma reported findings from two new analyses from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.

  • In June 2019, Genentech, Inc. received Food and Drug Administration approval to polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.), a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).


Cutaneous B-cell Lymphoma Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2020
  • 2017-2019

    CHOOSE LICENSE TYPE

  • $4850
    $6850
    $8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Styker
Johnson
iqvia
Ipsos
Roche

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X